Abivax ABVX.PA
Abivax is a clinical-stage biopharmaceutical company developing therapies for inflammatory and immunological diseases, with its lead candidate focused on ulcerative colitis. Abivax is a clinical-stage biotech with an operating margin of -8617% and ROE of -252%, burning cash without generating revenue; positive momentum (34.9%) and key appointments do not offset the structural funding risk.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Abivax is a clinical-stage biopharmaceutical company developing therapies for inflammatory and immunological diseases, with its lead candidate focused on ulcerative colitis. Abivax is a clinical-stage biotech with an operating margin of -8617% and ROE of -252%, burning cash without generating revenue; positive momentum (34.9%) and key appointments do not offset the structural funding risk.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.1 |
| Quality / Moat | 3.3 |
| Valuation | 0.6 |
| Growth | 2.3 |
| Dividend | 1.5 |
| Momentum | 6.8 |
| Risk & Context | 8.0 |
OVERALL SCORE: 3.7/10
Context and risks
Clinical-stage biotech without revenue: funding risk is structural. The high-rate environment makes future capital rounds more expensive, but the main risk is the pre-revenue business model itself, not the macro.
News considered in the analysis
- ABIVAX Société Anonyme (ENXTPA:ABVX) Just Gave Investors Something To Think About — Titular vago de Simply Wall St. sin información concreta sobre resultados o valoración; no aporta datos accionables.
- ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers — Nombramiento de directivos médicos y técnicos clave en una biotecnológica en fase clínica; refuerza la capacidad de ejecución del programa principal, aunque el impacto en valor es moderado.
- ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch? — El aumento del consumo de caja es un hecho ya ocurrido y típico en biotecnológicas pre-ingresos; la pregunta sobre financiación hasta el lanzamiento es relevante pero no nueva.
- Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why — Upgrade de analista a Comprar; señal moderadamente positiva que puede atraer flujo, aunque no cambia los fundamentales.
- AbbVie Q2 Earnings Call Highlights — Noticia sobre AbbVie, no sobre Abivax; irrelevante para esta empresa.
Verdict: Avoid until it demonstrates clear clinical progress and a sustainable funding path; the risk profile is high.
Main risk: Funding risk: with an operating margin of -8617% and increasing cash burn, the company depends on future capital raises to survive until a potential launch.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →